[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"treatment-outcomes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:treatment-outcomes":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100467293","prehabilitation-for-ovarian-cancer-patients-100467293",false,"NCT05364879","Prehabilitation for Ovarian Cancer Patients","The Impact of Prehabilitation Exercise on Frailty and Treatment Outcomes in Ovarian Cancer Patients","Inclusion Criteria:\n\n* 18 years or older\n* Have a confirmed diagnosis of stage III or IV ovarian cancer\n* Scheduled to receive cytoreductive surgery as part of their treatment plan\n* Must have a minimum of 4-weeks between the time of study enrollment and scheduled surgery\n* Be able to attend in-person and\u002For virtual exercise sessions\n* Be fluent in English\n* Have oncologist approval\n\nExclusion Criteria:\n\n* Have already completed surgery\n* Unstable cardiac or respiratory disease, injury or any other co-morbid disease that may make it unsafe for participants to exercise\n* Significant cognitive impairment (e.g., do not have the capacity to consent, unable to follow exercise instructions)","FEMALE","18 Years",{"count":19,"type":20},108,"ESTIMATED","INTERVENTIONAL",[23],"NA","Individuals with ovarian cancer have very poor survival rates. This is because the cancer is not usually detected until it has reached advanced stages. How long an individual survives also is determined by the cancer treatment they receive. Although there are best treatment practices to improve survival, some women have other conditions that limit treatment options. One such condition seen in as many as 50% of women with advanced ovarian cancer is frailty (an age-related decline in function and health). This is a major concern as doctors will often have to change how the cancer is treated based on the patient being frail. For example, patients living with frailty are less likely to have their full tumor removed during surgery. They are also more likely to have complications with surgery, stay in the hospital longer, and recover less well from surgery overall. Patients living with frailty also are more likely to experience delays in their chemotherapy starting, receive lower doses of chemotherapy and\u002For receive fewer cycles of chemotherapy. These changes in treatment may decrease how long a patient survives after diagnosis. Thus, research is needed to explore strategies to decrease frailty in patients who require treatment for advanced ovarian cancer. An option gaining more attention is physical exercise (e.g. walking, repeatedly rising from a chair). Exercise performed before surgery, which is called prehabilitation, can improve how well a patient recovers after surgery and increase how long they survive. Research has shown that prehabilitation is very beneficial for patients undergoing surgery for heart disease. However, it is not clear whether prehabilitation works for those with advanced ovarian cancer that are going to have surgery. Therefore, the investigators want to explore how a 4+ week exercise program performed while waiting for surgery for advanced ovarian cancer changes frailty and how a patient recovers after surgery. The investigators will specifically look whether the exercise program: 1) reduces how frail a patient is before surgery; 2) improves how well the patient recovers after surgery; and 3) affects the patient's chemotherapy treatment plan. This study will provide important information about the ability of prehabilitation exercise to improve surgical and treatment outcomes in women with advanced ovarian cancer. Overall, it is believed that exercise has the potential to improve the survival of advanced ovarian cancer patients.",[26,27,28,29,30,31,32],"Prehabilitation","Exercise","Frailty","Ovarian Cancer","Surgical Complication","Treatment Outcomes","Enhanced Recovery After Surgery","RECRUITING","2026-05-28",{"date":36,"type":37},"2026-06-01","ACTUAL",{"date":39,"type":37},"2023-01-03",{"date":41,"type":20},"2027-08-31",{"name":43,"class":44},"Nova Scotia Health Authority","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100568375","epithelioid-haemangioendothelioma-observational-study-100568375","NCT06680401","Epithelioid Haemangioendothelioma Observational Study","The Evaluation of Cytokines and Hormones as Biomarkers for Epithelioid Haemangioendothelioma and Generation of Patient-derived Preclinical Models to Assess the Activity of Anticancer Agents and Validate Novel Therapeutic Targets","Inclusion Criteria:\n\n* Histological diagnosis of EHE according to 2020 WHO classification, performed on biopsy or surgical specimen\n* Signed informed consent\n* Adequate patient compliance to treatment or follow up\n* No age limit\n\nExclusion Criteria:\n\n* Impossibility to ensure adequate compliance","ALL",{"count":55,"type":20},50,"OBSERVATIONAL","The EHE observational study was developed to obtain a high number of datas such as clinical presentation, natural history, and treatment outcomes, cto identificate cytokines and hormones as biomarkers and generate patient-derived preclinical models as a tool to assess the activity of anticancer agents and validate novel therapeutic targets",[59,60,31],"Clinical Presentation","Natural History","2026-03-27",{"date":63,"type":37},"2026-04-01",{"date":65,"type":37},"2021-02-25",{"date":67,"type":20},"2028-12",{"name":69,"class":44},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":45},"100619406","guard-ph-guided-use-of-ai-ecg-for-risk-detection-of-ph-in-surgery-guard-ph-trial-100619406","NCT07344207","GUARD-PH: Guided Use of AI-ECG for Risk Detection of PH in Surgery (GUARD-PH Trial)","A Prospective, Open-Label, Randomized Controlled Trial of an Artificial Intelligence Enabled Electrocardiography System for Preoperative Detection of Pulmonary Hypertension and Related Diseases(GUARD-PH)","GUARD-PH","Inclusion Criteria:\n\n1. Age between 18 and 80 years.\n2. Patients scheduled for non-cardiac surgery under general anesthesia.\n3. Patients who have a scheduled standard preoperative electrocardiogram (ECG).\n4. Patients capable of understanding the study and willing to provide medical records for research purposes, and who have signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients scheduled for emergency surgery.\n2. Patients who explicitly refuse to participate or withdraw consent.\n3. Patients with specific comorbidities that interfere with ECG interpretation or data collection (e.g., implanted pacemakers).",{"count":79,"type":20},1380,[23],"This study is a prospective, open-label, randomized controlled trial designed to evaluate a new artificial intelligence (AI) tool for heart monitoring. Researchers will use an AI-enabled electrocardiography (ECG) system to screen patients before they undergo surgery. The main goal is to determine if this AI system can accurately detect pulmonary hypertension and related heart diseases in the preoperative setting. The study is being conducted at Taipei Veterans General Hospital.",[83,84,85,31],"Pulmonary Hypertension (Diagnosis)","Pre-operative Assessment","Postoperative Complications (Cardiopulmonary)",[87,88,89,90,91],"Artificial Intelligence","Electrocardiography","AI-ECG","Preoperative Detection","Screening","NOT_YET_RECRUITING","2026-01-07",{"date":95,"type":37},"2026-01-15",{"date":97,"type":20},"2026-01-05",{"date":99,"type":20},"2027-01-05",{"name":101,"class":102},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV"]